(ASX:IMM) has announced that the first patient has been enrolled and safely dosed in INSIGHT-003 study that includes its LAG-3 investigative immunotherapy.
The patient with metastatic non-small cell lung carcinoma received MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immutep’s lead product candidate eftilagimod alpha (efti).
INSIGHT-003 is evaluating the triple combination therapy consisting of efti in conjunction with an existing approved standard of care combination of chemotherapy and the anti-PD-1 therapy.
The company said the study will continue to recruit up to 20 patients with various solid tumours and first results are expected in the calendar year 2022.
Immutep’s Dr Frédéric Triebel said, “INSIGHT-003 is the first time a triple combination therapy consisting of efti plus anti-PD-1 plus chemo is administered. We are evaluating how efti might boost an approved chemotherapy and anti-PD-1 combination therapy, looking at safety and initial activity.
“Dosing the first patient in this trial is a significant milestone and it sets the wheels in motion for reporting first data which are currently anticipated in 2022.”
The INSIGHT-003 study is an investigator-initiated trial conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. It is being run as the third arm (Stratum C) of the ongoing phase 1 INSIGHT trial with Professor Dr Salah-Eddin Al-Batran as lead investigator.